Difference in cardiovascular activities of CPU-86017 between rat and rabbit by iv and icv routes, and potential relation to endothelium

Journal of China Pharmaceutical University

Volumn 33, Issue 5, 2002, Pages 428-433

  Ciamala, Cibangu D ^a   Wang, Zi Zheng ^b   Dai, De Zai ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b No 1 Municipal Hospital of Nanjing   (China)

Author keywords

Blood pressure; CPU 86017; Heart rate; NO; NOS

Indexed keywords

ANTIHYPERTENSIVE AGENT; CANADINE; CPU 86017; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG EFFECT; ELECTROCARDIOGRAM; FEMORAL VEIN; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOTENSION; NONHUMAN; RABBIT; RAT; SPECIES COMPARISON; VASCULAR ENDOTHELIUM;

EID: 29644432360     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Gregoratos G, Weitz H, Adolph RJ, et al. In: Cardiovascular medicine. Independence Mall West. Philadelphia, Pennsylvania 19106-1572. USA. 1998, 189.
2. Puscas L, Gilau L, Coltau M, et al. Calcium channel blockers reduce blood pressure in part by inhibiting vascular smooth muscle carbonic anhydrase I[J]. Cardiovasc Drugs Ther, 2000, 14 (5): 523-8.
3. Dai DZ, Yu F, Li HT, et al. Blockade on Sodium, Potassium, and Calcium Channels by a new antiarrhythmic agent CPU 86017 [J]. Drug Dev Res, 1996, 39:138-146.
4. Dai DZ. The anti-arrhythmic activity of Protoberberines in relation to blockade of ion channels[J]. Ion Chan Modulators, 1997, 2:383-390.
5. Ciamala CD, Lin S, Liu WT et al. Disposition and blood brain barrier of CPU-86017 (P-chlorobenzylletrahydroberberine) after intravenous and intra-cerebrovenitricular in mice. J China Pharm Uni. 2002,34(3):226-230.
6. Ciamala CD, Lin S, Dai DZ. Permeability of CPU-86017 through the BBB after intravenous and intracerebroventricular injection in mice. The International Sysposium Proceedings: Cardiovascular Remodeling, Ion channolopathies, Arrhythmias and Drug Treatment. 2001. 47.
7. Unger Th, Rascher W, Schuster C, et al. Central blood pressure effects of substance P and angiotensin II: role of the sympathetic nervous system and vasopressin[J]. Eur J Pharmacol, 1981, 71: 33-42.
8. Wang YQ, Chao P, Dai DZ. Influence of 86017 on haemodynamic in anaesthetized rabbits and rats[J]. Bull New Drug Res Found, 1991, 1: 99-103.
9. Briand V, Laurent S, Tsoucaris-Kupfer D, et al. Central and peripheral cardiovascular effects of the enantiomers of the calcium antagonist PN 200-110. Eur. J Pharmacol, 1988, 150:43-50.
10. Brisac AM, Huguet F, Champeroux P, et al. Central interactions between dihydropyridine and cholinergic system in the control of blood pressure in rat[J]. Brain Res, 1987, 435:160-166.
11. Chen K. and Zimmerman BG. Comparison of renal hemodynamic effect of ramiprilat to captopril; possible role of kinins[J]. J Pharmacol Exp Ther, 1994, 270(2): 491-497.
12. Miyasaka K. and Hiramatsu Y. Pharmacological studies of lycorenine, an alkaloid of Lycoris radiata Herb. II. Effects of blood pressure in rats and dogs and the mechanism of tachyphylaxis to the vasodepressor action of lycorenine in rats[J]. Japan J Pharmacol, 1980, 30:655-664.
13. Tousoulis D, Davis GJ, Toutouzas PC. Vasomotion of coronary arteries: From nitrates to nitric oxide[J]. Cardiovascular Drugs Ther, 1999, 13:295-300.
14. Nava E, Rodriguez F, Moreno C, Llinas MT, and Salazar FJ. Release of Nitric Oxide after acute hypertension. J Cardiovasc Pharmacol, 2000, 36: 444-450.